BioSpace News Archive

DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare diseases and oncology that target the protein tyrosine phosphatase (PTP) family of enzymes.

Masimo Corporation filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its Annual Meeting of Stockholders to be held on June 26, 2023.

Taglich Brothers, Inc. announces that it has initiated coverage of Ocean Biomedical, Inc.

Pinetree Therapeutics, Inc. announced the addition of Pamela A. Trail, PhD, to its Scientific Advisory Board as well as the appointment of John Majercak, PhD, as Chief Technology Officer.

Medivir AB announces that the number of shares and votes in Medivir has changed during May 2023 as a result of the previously announced share issue of 970,500 shares of series C and the reclassification of 105,750 shares of series C into ordinary shares, which was carried out as part of the long-term incentive program for key employees within the Medivir group adopted by the annual general meeting held on 4 May 2023.

HighField Biopharmaceuticals, a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced the publication of an abstract including preliminary data from a Phase 1a clinical trial of HF1K16 in refractory metastatic cancer patients.

ICON plc announced that Dr. Steve Cutler, CEO of ICON plc, will present at the William Blair 43rd Annual Growth Stock Conference on Tuesday, June 6, 2023 at 2:40pm CT and Mr. Brendan Brennan, CFO of ICON plc, will attend the UBS Healthcare Services Conference on Wednesday, June 28, 2023.

Marker Therapeutics, Inc. announced pre-clinical data from the Company’s multiple tumor-associated antigens -specific T cell product candidate MT-601 in lymphoma cells, including CD19 CAR T refractory cells.

KalVista Pharmaceuticals, Inc. announced it will present at the Jefferies Global Healthcare Conference on Wednesday, June 7th, 2023 at 2:00 p.m. ET in New York, NY.

Analog Pharma (member of Duchesnay Pharmaceutical Group, hereafter “Analog”) and Dipharma S.A. (“Dipharma”) are pleased to announce that their 20 mg nitisinone abbreviated new drug application (ANDA) has received final approval from the U.S. Food and Drug Administration.